Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01347710 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
A Phase 3 study, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
NCT01347710 is a Phase 3 study that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 795 participants.
The verdict
NCT01347710, a Phase 3 study, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).
Interventions
- DRUG Flurpiridaz F18
- DRUG 99mTechnicium (sestamibi or tetrofosmin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01347710
The ClinicalTrials.gov registry entry for NCT01347710 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 795 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flurpiridaz F18 is the first listed.
NCT01347710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01347710 about?
NCT01347710 is a clinical study titled "A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.". The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) a...
What is the current status of trial NCT01347710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2011-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01347710?
The interventions under investigation include: Flurpiridaz F18 (DRUG), 99mTechnicium (sestamibi or tetrofosmin) (DRUG).
Who is sponsoring clinical trial NCT01347710?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.